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724Objectives: To determine if there are advantages to transitioning to robotics by a surgeon who is already
proficient in performing video-assisted thoracic surgical (VATS) lobectomy.
Methods: A single surgeon proficient in VATS lobectomy initiated a robotic lobectomy program, and a
retrospective review was conducted of his patients undergoing minimally invasive lobectomy (robotics or
VATS) for lung cancer between 2011 and 2012. Data collected included patient/tumor characteristics, morbidity,
mortality, operative times, and length of hospital stay.
Results: Over a 24-month period, a total of 69 patients underwent minimally invasive lobectomy (35 robotic,
34 VATS). Patients in each group were similar in age and clinical stage. Robotic upper lobectomy operative
times were longer than VATS (172 vs 134 minutes; P ¼ .001), with no significant difference in lower
lobectomies noted (140 vs 123 minutes; P ¼ .1). Median length of stay was 3 days in both groups, and the
median number of lymph nodes harvested was 18 (robotic) versus 16 (VATS; P¼ .42). Morbidity and mortality
for robotic versus VATS were 11% versus 18% (P ¼ .46) and 0% versus 3% (P ¼ .49), respectively.
Conclusions: There does not seem to be a significant advantage for an established VATS lobectomy surgeon to
transition to robotics based on clinical outcomes. The learning curve for robotic upper lobectomies seems to be
more significant than that for lower lobectomies. (J Thorac Cardiovasc Surg 2014;147:724-9)Video-assisted thoracic surgical (VATS) lobectomy was
first performed in 1992 and has since been proved to be
oncologically equivalent and perhaps even superior to
traditional lobectomy by thoracotomy.1-3 In addition,
patients undergoing VATS lobectomy have been shown to
have fewer complications, decreased pain, shorter lengths
of stay, improved recovery, and better tolerance of
adjuvant chemotherapy.4-6 However, despite these
advantages VATS lobectomy has not been widely used.
Recent studies suggest that less than 50% of lobectomies
performed in the United States are performed using VATS.7
Robotic lobectomy has recently come to the forefront as a
new platform for minimally invasive thoracic surgery.
Initial results of robotic lobectomy have shown the
same benefits achieved with VATS compared with open
thoracotomy are maintained.8-10 Moreover, proponents of
robotic surgery claim additional benefits of improved
ergonomics, three-dimensional optics, and wristed
instrument motions, which may allow for a more thorough
lymph node dissection.11-13 On the other hand, opponents ofaniel and Gloria Blumenthal Cancer Center,a Paramus, NJ; and Division of
cic Surgery,b Department of Surgery, The Valley Hospital/Valley Health
m, Ridgewood, NJ.
res: Authors have nothing to disclose with regard to commercial support.
the 39th Annual Meeting of The Western Thoracic Surgical Association,
r d’Alene, Idaho, June 26-29, 2013
d for publication June 25, 2013; revisions received Aug 7, 2013; accepted for
ation Oct 6, 2013; available ahead of print Nov 18, 2013.
for reprints: Benjamin E. Lee, MD, 1 Valley Health Plaza, Paramus,
652 (E-mail: leebe@valleyhealth.com).
23/$36.00
ht  2014 by The American Association for Thoracic Surgery
.doi.org/10.1016/j.jtcvs.2013.10.002
The Journal of Thoracic and Cardiovascular Surgrobotic surgery have cited increased costs and longer
procedure times.14
Despite a growing body of literature regarding robotic
lobectomy, there is a paucity of information on whether or
not there are advantages to transitioning to robotics by
surgeons who are already proficient in performing VATS
lobectomy. As a result, we chose to evaluate this transition
in the context of our own thoracic surgery program to
determine if any advantages exist.
PATIENTS AND METHODS
Study Design and Patient Cohort
This study presents a retrospective review of a prospectively collected
and maintained surgical database of patients with lung cancers. The
Institutional Review Board waived the need for informed consent. From
January 2011 to December 2012, all patients who underwent a
thoracoscopic lobectomy performed by a single surgeon (B.E.L.) by either
conventional VATS (VL) or robotics (RL) for the treatment of biopsy
proven or suspected lung cancer were included. In addition, all operations
(VL and RL) were performed with the same physician’s assistant (E.K.) at
the bedside. Patients were excluded if the initial surgical plan for resection
was to use a thoracotomy. The determination of the minimally invasive
surgical approach was not random in this study. Patients from January
2011 to February 2012 all underwent VL. Our program initiated its RL
program in March 2012 and unless scheduling conflicts did not allow for
access to robotics, all patients underwent lobectomy by RL from March
2012 until the end of this study. Patients who underwent treatment with
neoadjuvant chemotherapy and/or radiation therapy were included.
Surgeon Background
B.E.L. is a fellowship trained thoracic surgeon competent in VATS
lobectomy with more than 200 previous cases. Previous robotics
experience included using robotic surgery for thymectomy and mediastinal
tumors. No formal training in RL was obtained other than observation of a
few cases.ery c February 2014
Abbreviations and Acronyms
VATS ¼ video-assisted thoracic surgery
VL ¼ VATS lobectomy
RL ¼ robotic lobectomy
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STechnique of VATS and RL
All procedures were performed in the lateral decubitus position with
hilar dissection and individual ligation of hilar structures. VATS lobectomy
used 2 incisions: a 4-cm anterior utility incision placed in the fourth or fifth
intercostal space and 1 additional 12-mm camera port incision as
previously described.1 Rib spreading was not used in any VATS procedure.
For RL, a complete portal system with a 4-armed approach was used
(DaVinci S, Intuitive Surgical, Sunnyvale, Calif). One additional 12-mm
assist port was placed in the anterior costophrenic region. Three reposable
instruments were used for the cases: the PK Dissecting Forceps, a double
fenestrated grasper, and the Prograsp forceps (Intuitive Surgical,
Sunnyvale, Calif). All hilar structures were individually dissected and
ligated using automatic stapling devices. Fissures were completed with
either sharp dissection or an automatic stapling device. The anterior
costophrenic port was enlarged near the end of the procedure to allow
for specimen retrieval. Systematic mediastinal and hilar lymph node
dissections were performed for all cases. Lymph node stations addressed
typically included paratracheal (4R), tracheobronchial angle (10R),
subcarinal (7), interlobar (11) and infrahilar (9) for right-sided resections
and periaortic (5), subcarinal (7), tracheobronchial angle (10L), interlobar
(11), and infrahilar (9) for left-sided resections. Specimens were placed in
impervious bags (Endocatch II 15-mm specimen pouch, Covidien,
Norwalk, Conn).
Data Collection and Definitions
Data collected included patient demographics, age, gender, smoking
status, pulmonary function test data, tumor characteristics (location,
histology, size, and clinical and pathologic stage), lymph node data
(number removed and stations dissected), administration of neoadjuvant
therapy, performance of invasive mediastinal staging, operative data
(operative time, number of stapler loads used), length of hospital stay,
and morbidity and mortality.
Operative time was defined as the time from the initial incision until the
completion of wound closure. For robotic cases, this included the time
needed for docking and undocking. Conversion was defined as the need
to use a rib-spreading thoracotomy or the need to switch from robotic to
conventional VATS. All perioperative adverse events were recorded and
perioperative deaths were defined as any death occurring during the
primary hospitalization or within 30 days after surgery. Prolonged air leaks
were defined as lasting 7 days or longer, discharge of a patient with a chest
tube in situ, and/or the need to perform bedside pleurodesis. Length of stay
was defined using postoperative days. Clinical and pathologic staging was
performed using the seventh edition of the American Joint Commission on
Cancer staging manual.
Statistical Analysis
Categorical variables were compared using c2 tests, and continuous var-
iables were compared using nonparametricWilcoxon-Mann-Whitney tests.
IBM-SPSS Statistics software (version 19) was used for all analyses.13RESULTS
Patient Characteristics
Sixty-nine patients met the inclusion criteria for this
study. The clinical characteristics of the study cohort areThe Journal of Thoracic and Capresented in Table 1. There were 35 patients in the RL group
and 34 patients in the VL group. During the period when
mainly RL was used, 3 patients underwent VL because of
lack of access to robotics. There were no significant
differences in age, smoking status, pulmonary function,
median tumor size, tumor histology, tumor location, or
clinical stage between the 2 groups. However, there was a
higher percentage of men in the RL group (Table 1).
Neoadjuvant chemoradiotherapy was administered to
4 patients in the RL group; none of the patients underwent
this treatment in the VL group.
Operative Results
There were no conversions to conventional VATS in the
robotic group. There was 1 conversion to thoracotomy in
the RL group due to the tumor crossing the major fissure
and an inability to safely dissect the pulmonary artery.
Within the RL group, 1 patient had a bilobectomy
(right middle lobe þ right lower lobe) and another had a
combined lobectomy and segmentectomy (right upper
lobe þ right lower lobe superior segment). One patient
who underwent VATS also had a combined lobectomy
and segmentectomy (right lower lobe þ right upper lobe
posterior segment). No patients required blood transfusions.
Differences in operative time, stapler loads used, lymph
node data, length of hospital stay, morbidity and mortality
between the 2 groups of patients are presented in Table 2.
Within the VL group, 5 patients had nodal upstaging
(4 from stage 1 to stage 2, 1 from stage 1 to stage 3).
No patients in the RL group had nodal upstaging.
With regard to morbidity in the RL group, 2 patients had
postoperative atrial fibrillation, 1 had a prolonged air leak,
and another developed empyema that was treated by tube
thoracostomy. The VL group included 3 patients with
prolonged air leaks, 1 patient with severe delirium, and
1 patient requiring bedside bronchoscopy for mucous
plugging. One patient also presented 3 weeks after
discharge with an acute pulmonary embolism that resulted
in death.
Effect of Induction Chemoradiotherapy onOperative
Time
In the 4 patients undergoing RL after receiving induction
chemoradiotherapy, the median operating time was
245 minutes, compared with 152 minutes in the 31 patients
who did not receive induction therapy (P ¼ .001). Two
of these 4 RL patients underwent lobectomies; 1 required
a bilobectomy and another required a lobectomy/
segmentectomy.
Effect of Tumor Location on Operative Time
Figure 1 depicts the 3-case average times for all robotic
lobectomies in this study. The 3-case average times are
shown in Figures 2 and 3 for operative times segregatedrdiovascular Surgery c Volume 147, Number 2 725
TABLE 1. Patient characteristics (N ¼ 69)
VATS
(n ¼ 34)
Robotic
(n ¼ 35)
P
value
Age, median years (range) 77 (52-88) 71 (52-84) .06
Male sex, no. (%) 8 (24) 22 (63) .001
Smoking status, no. (%)
Never 10 (29) 6 (17) .46
Former 9 (56) 22 (63)
Current 5 (15) 7 (20)
FEV1% predicted, median (IQR) 89 (72-100) 81 (65-91) .17
DLCO% predicted, median (IQR) 77 (57.5-95) 81 (74-90) .27
Primary tumor location, no. (%)
Right upper lobectomy 9 (27) 15 (43) .43
Right middle lobectomy 2 (6) 1 (3)
Right lower lobectomy 10 (29) 10 (29)
Left upper lobectomy 9 (27) 4 (11)
Left lower lobectomy 4 (12) 5 (14)
Histology, no. (%)
Adeno 27 (79) 25 (71) .72
Squamous 4 (12) 4 (11)
Small cell 1 (3) 1 (3)
Carcinoid 2 (6) 5 (14)
Tumor size, median cm (range) 2.5 (1.1-13) 2.0 (1-14) .32
Mediastinal staging, no. (%) 17 (50) 16 (46) .72
Neoadjuvant therapy, no. (%) 0 (0) 4 (11) .11
Clinical stage, no. (%)
IA 19 (56) 20 (57) .73
IB 9 (26) 6 (17)
IIA 3 (9) 2 (6)
IIB 1 (3) 3 (9)
IIIA 1 (3) 3 (9)
IVB 1 (3) 1 (3)
VATS, Video-assisted thoracoscopic surgery; FEV1, forced expiratory volume in
1 second; IQR, interquartile range; DLCO, diffusing capacity of lung for carbon
monoxide.
TABLE 2. Perioperative outcomes
VATS
(n ¼ 34)
Robotic
(n ¼ 35)
P
value
Overall operative time,
median minutes (range)
128 (71-237) 161 (104-272) <.001
Upper lobectomy,
median minutes (range)
134 (92-222) 172 (118-240)
Lower lobectomy,
median minutes (range)
123 (71-237) 140 (104-272)
Stapler loads, median no. (range) 9 (5-23) 9.5 (5-13) .74
Lymph nodes removed,
median no. (range)
16 (2-44) 18 (4-77) .42
Lymph node stations dissected,
median no. (range)
2 (1-3) 3 (2-4) .14
Length of stay, median days (IQR) 3 (2-4) 3 (2-6) .67
Morbidity, no. (%) 6 (18) 4 (11) .46
Mortality, no. (%) 1 (3) 0 (0) .49
Pathologic stage, no. (%)
IA 16 (47) 22 (63) .64
IB 6 (18) 5 (14)
IIA 6 (18) 2 (6)
IIB 3 (9) 2 (6)
IIIA 2 (6) 3 (8)
IVB 1 (3) 1 (3)
VATS, Video-assisted thoracoscopic surgery; IQR, interquartile range.
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lower lobe resections). Overall, when comparing RL and
VL, there was no difference in the median operative time
for lower lobectomies (140 vs 123 minutes, P ¼ .10).
However, for upper lobectomies, the operative time for
RL was significantly longer than that for VL (172 vs 134
minutes, P ¼ .001).DISCUSSION
The use of robotics represents an alternative approach to
VATS as a minimally invasive operative strategy for
lobectomy in patients with lung cancer. Although the
literature suggests that RL offers similar advantages over
traditional thoracotomy as VL, it is unclear if proficient
VL surgeons should invest the time and resources necessary
to learn the robotic approach, because they are already
practicing a minimally invasive technique. The present
study was undertaken to determine if clinically meaningful
advantages of RL can be demonstrated over VL, in the
context of a single surgeon who was already proficient in726 The Journal of Thoracic and Cardiovascular Surgthe performance of VL. In this regard, the data show that
no demonstrable advantages of RL exist over VL across
multiple clinical end points in this setting. The learning
curve for robotic upper lobectomy seems to be more
significant than that for robotic lower lobectomy. These
findings have implications for proficient VATS lobectomy
surgeons who are considering transitioning to a robotic
approach.
Differences Between VATS and Robotics
This study demonstrates that there are few differences
between RL and VL for multiple clinical end points when
an established VATS surgeon initiates an RL program. A
clear strength of the present study is that it describes the
experience of a single surgeon, thereby eliminating any
potential effect of surgeon variability on the results. These
findings are consistent with those reported by Jang and
colleagues,15 where the addition of the robot did not change
outcomes over a VATS approach alone. One difference
between the 2 approaches in the present study, however,
was the number of incisions used: 4 or 5 incisions were
used for the robotic cases and 2 in the VATS cases. More
incisions may potentially translate into more postoperative
pain, however this end point was not measured. No effect of
the larger number of incisions was able to be measured in
terms of morbidity, and therefore the difference in the
number of incisions may not be clinically relevant.
Operative time was also longer for RL cases compared
with VL. However, this difference was mainly attributableery c February 2014
FIGURE 1. Operative time for RL. Three-case average operative case times are shown for consecutive cases and plotted against the overall average for
VATS lobectomy. VATS, Video-assisted thoracic surgery.
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for lower lobes. Over time, the operative times for upper
lobe RL also approached the VL times, suggesting that
once the robotic learning curve is completed, minimal
difference in operative times may exist.
Learning Curves for Robotic Upper Versus Lower
Lobectomy
From a technical perspective, it is understandable that
upper lobe resections are more time consuming as there
are typically more individual pulmonary arterial branches
that require dissection. Moreover, our technique for lower
lobectomy was similar using both VATS and roboticFIGURE 2. Operative time for robotic upper lobectomy. Three-case average o
overall average for VATS upper lobectomy. VATS, Video-assisted thoracic surg
The Journal of Thoracic and Caapproaches with division of the pulmonary vein followed
by the bronchus and finally the pulmonary artery. On the
other hand, our VATS upper lobectomies are typically
approached from an anterior to posterior dissection
(eg, vein, artery, bronchus). We initially performed robotic
upper lobectomies in the same manner, but we found
visualization and exposure to be difficult at times, which
resulted in lengthy case times. As a result of experimenting
with different approaches, we have found robotic right
upper lobe resections to be more easily approached from
the posterior to anterior direction (eg, bronchus, artery,
vein) and robotic left upper lobe resections more easily
approached through the fissure (lingular artery, vein,perative case times are shown for consecutive cases and compared with the
ery.
rdiovascular Surgery c Volume 147, Number 2 727
FIGURE 3. Operative time for robotic lower lobectomy. Three-case average operative case times are shown for consecutive cases and compared with the
overall average for VATS lower lobectomy. VATS, Video-assisted thoracic surgery.
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may have resulted in the more significant learning curve
seen with robotic upper lobectomies. Our surgical approach
may differ from other centers but it is evident that
comparable cases times are achievable for RL.
Costs of RL
A cost analysis of RL that is applicable to all robotic
programs is somewhat problematic because the cost of the
robotic platform varies between institutions. The theoretic
amortized cost of robotics includes the price of the robotic
system divided by the number of cases performed. This
varies from one institution to another given that some
systems are purchased and others might be donated.
Moreover, the number of robotic cases and usage by
different surgical disciplines may vary between institutions.
Similarly, the cost of a VATS platform also varies between
programs. Although it is intuitive that the base cost of
robotics is higher than VATS, the ability to assign a
universal cost per case of the robot itself is not readily
feasible and comparable between institutions.
The present study attempts to address cost from the
perspective of tangible costs for RL versus VL. These
consist of intraoperative as well as postoperative costs.
Intraoperative costs include disposable instrumentation,
operative time, and personnel. RL cases in this series only
required approximately 30 minutes of additional operative
time, and no additional personnel were required over the
VL cases. There was also no difference in stapler cartridge
usage. From the postoperative standpoint, patients who
underwent RL and VL were managed identically, and
postoperative length of stay was no different between the728 The Journal of Thoracic and Cardiovascular Surgprocedures. Based on these comparisons, there seemed to
be a negligible difference in these costs between RL andVL.Should an Established VATS Lobectomy Surgeon
Learn RL?
Although the present study demonstrates no clinically
significant patient or economic benefits for an established
VATS lobectomy surgeon to convert to RL, there may be
other reasons not addressed in the present study as to why
this transition may be important to consider. First, robotic
technology may be advantageous for the performance of
other thoracic surgical procedures, and the performance of
RLmay help keep the surgeon facile at robotic surgery. Sec-
ond, robotic technology will continue to evolve, and more
clearly delineated benefits of robotic surgery may become
reality in the future for thoracic surgeons. Third, although
not addressed in the present study, the addition of robotics
may be beneficial for more advanced cases of lobectomy
for lung cancer. Specifically, in cases with difficult nodal
dissections, the wristed movements of the robotic instru-
ments combined with the enhanced field of vision associ-
ated with robotics may facilitate the minimally invasive
resection of more locally advanced cases. However, this
remains speculation and needs to be addressed in future
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